The phrase "a landmark phase" is correct and usable in written English.
It can be used to describe a significant or pivotal period in a process, project, or development.
Example: "The company is entering a landmark phase in its growth, with new innovations set to revolutionize the industry."
Alternatives: "a pivotal stage" or "a significant period".
8– 13, 14, 14 In a landmark Phase III trial that assessed the efficacy of bevacizumab alone or in combination with irinotecan in recurrent glioblastoma, HTN was more frequent in the bevacizumab alone arm.
Recently this was clearly demonstrated in breast cancer, with the development of the poly(ADP-ribose) polymerase inhibitor olaparib in a landmark phase I trial, whereby patients with BRCA1 or BRCA2 mutations were enrolled [ 8].
The LIFE Study is a landmark Phase III randomized controlled clinical trial that will provide definitive evidence regarding the effect of exercise on major mobility disability – failure to complete a self-paced 400 m walk in ≤15 minutes – in older adults, aged 70 89 years who have compromised physical function.
In a landmark phase III study by Bonner et al (2010), Cetuximab combined with radiotherapy vs definitive radiotherapy alone at 5 years demonstrated significant benefits in median duration of overall survival (49 vs 29.3 months, P=0.03) in patients with SccH&N.
In 2005, a landmark phase III trial (Stupp et al, 2005) described the efficacy the new therapeutic agent temozolomide: when given together with radiotherapy and as adjuvant therapy there were significant increases in median survival (14 vs 12 months, P<0.001), 2-year survival and progression-free survival compared with radiotherapy alone.
Substantial reductions in major adverse cardiovascular events and all-cause mortality without significantly increased overall major bleeding complications were observed in the PLATO trial, a landmark phase III study comparing ticagrelor with clopidogrel in a broad spectrum of ACS patients [ 2].
28 A subsequent landmark phase II trial of ofatumumab in fludarabine and alemtuzumab-refractory patients demonstrated an ORR of 47% 58% in both groups, with the most common adverse events being grade 1 2 infections or infusion reactions.
In a recently published landmark phase III trial of cisplatin plus gemcitabine versus gemcitabine alone for the treatment of BTC, no complete responses were seen among 117 gallbladder cancer patients treated [ 3].
In 2006, results were reported from a landmark, randomized phase III trial of HNSCC patients with locally advanced disease that compared cetuximab plus radiation to radiation alone [26].
In the landmark phase III study 50% of the patients required a dose reduction of sunitinib due to these events (Motzer et al, 2008a, 2008b).
For example, the incidence of hand-foot syndrome (55% in a Japanese study (Akaza et al, 2007) vs 30% in the initial landmark phase III study (Escudier et al, 2007)) and hypertension (28% (Akaza et al, 2007) vs 17% (Escudier et al, 2007)) with sorafenib in Japanese patients were higher compared with those in clinical trial populations that enrolled few Asians.
